First wearable device designed to deliver leukemia treatment instead of intravenous injections

The U.S. Food and Drug Administration has approved a wearable version of Sarclisa for the treatment of multiple myeloma, offering patients a less burdensome alternative to the intravenous injection sessions that can last up to three hours. The new device is administered in approximately 13 minutes. This approval comes as part of an effort to expand treatment options and reduce treatment duration, with sales of the drug expected to reach €710 million by 2026.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل